NO20053201L - Nye heterocykliske fluorglukosidderivater, legemidler inneholdende disse forbindelser og deres anvendelse. - Google Patents

Nye heterocykliske fluorglukosidderivater, legemidler inneholdende disse forbindelser og deres anvendelse.

Info

Publication number: NO20053201L
Authority: NO; Norway
Prior art keywords: fluoroglucose; derivatives; compounds; drugs containing; new heterocyclic
Prior art date: 2002-12-12

Application number

NO20053201A

Other languages

English (en)

Other versions

NO330299B1 (no

NO20053201D0 (no

Inventor

Heiner Glombik

Hubert Heuer

Werner Kramer

Wendelin Frick

Harm Brummerhop

Oliver Plettenburg

Original Assignee

Aventis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-12

Filing date

2005-06-30

Publication date

2005-08-04

2005-06-30 Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh

2005-06-30 Publication of NO20053201D0 publication Critical patent/NO20053201D0/no

2005-08-04 Publication of NO20053201L publication Critical patent/NO20053201L/no

2011-03-28 Publication of NO330299B1 publication Critical patent/NO330299B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Child & Adolescent Psychology (AREA)
Dermatology (AREA)

NO20053201A 2002-12-12 2005-06-30 Heterocykliske fluorglukosidderivater, anvendelser derav, legemidler inneholdende forbindelsene samt fremgangsmate for fremstilling av legemidlene. NO330299B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10258008A DE10258008B4 (de)	2002-12-12	2002-12-12	Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
PCT/EP2003/013455 WO2004052903A1 (de)	2002-12-12	2003-11-28	Neue heterocyclische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (3)

Publication Number	Publication Date
NO20053201D0 NO20053201D0 (no)	2005-06-30
NO20053201L true NO20053201L (no)	2005-08-04
NO330299B1 NO330299B1 (no)	2011-03-28

Family

ID=32477575

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20053201A NO330299B1 (no)	2002-12-12	2005-06-30	Heterocykliske fluorglukosidderivater, anvendelser derav, legemidler inneholdende forbindelsene samt fremgangsmate for fremstilling av legemidlene.

Country Status (42)

Country	Link
US (2)	US20040259819A1 (no)
EP (1)	EP1572708B1 (no)
JP (1)	JP4806193B2 (no)
KR (1)	KR101160061B1 (no)
CN (1)	CN1304406C (no)
AR (1)	AR042437A1 (no)
AT (1)	ATE323713T1 (no)
AU (1)	AU2003289911B2 (no)
BR (1)	BR0317283A (no)
CA (1)	CA2508226C (no)
CR (1)	CR7820A (no)
CY (1)	CY1105621T1 (no)
DE (2)	DE10258008B4 (no)
DK (1)	DK1572708T3 (no)
EC (1)	ECSP055853A (no)
ES (1)	ES2261993T3 (no)
GT (1)	GT200300268A (no)
HN (1)	HN2003000408A (no)
HR (1)	HRP20050532A2 (no)
IL (1)	IL168876A (no)
JO (1)	JO2353B1 (no)
MA (1)	MA27560A1 (no)
ME (1)	MEP40908A (no)
MX (1)	MXPA05005821A (no)
MY (1)	MY139302A (no)
NO (1)	NO330299B1 (no)
NZ (1)	NZ540695A (no)
OA (1)	OA12972A (no)
PA (1)	PA8592301A1 (no)
PE (1)	PE20040771A1 (no)
PL (1)	PL212080B1 (no)
PT (1)	PT1572708E (no)
RS (1)	RS50908B (no)
RU (1)	RU2339641C2 (no)
SI (1)	SI1572708T1 (no)
SV (1)	SV2004001690A (no)
TN (1)	TNSN05160A1 (no)
TW (1)	TWI320044B (no)
UA (1)	UA81136C2 (no)
UY (1)	UY28122A1 (no)
WO (1)	WO2004052903A1 (no)
ZA (1)	ZA200503365B (no)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1020944C (zh)	1990-01-30	1993-05-26	阿图尔-费希尔股份公司费希尔厂	紧固件
DE10308353A1 (de)	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8785403B2 (en)	2003-08-01	2014-07-22	Mitsubishi Tanabe Pharma Corporation	Glucopyranoside compound
ES2649737T5 (es)	2003-08-01	2021-07-07	Mitsubishi Tanabe Pharma Corp	Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
CN103030617A (zh)	2004-03-16	2013-04-10	贝林格尔.英格海姆国际有限公司	吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
DE102004028241B4 (de)	2004-06-11	2007-09-13	Sanofi-Aventis Deutschland Gmbh	Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7393836B2 (en)	2004-07-06	2008-07-01	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200606129A (en)	2004-07-26	2006-02-16	Chugai Pharmaceutical Co Ltd	Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1773800A1 (de) *	2004-07-27	2007-04-18	Boehringer Ingelheim International GmbH	D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
JP5086643B2 (ja)	2004-11-18	2012-11-28	キッセイ薬品工業株式会社	１−置換−３−（β−Ｄ−グリコピラノシル）含窒素ヘテロ環化合物、及びそれを含有する医薬
WO2006064033A2 (en)	2004-12-16	2006-06-22	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637869A (en)	2005-01-28	2006-11-01	Chugai Pharmaceutical Co Ltd	The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR053329A1 (es) *	2005-01-31	2007-05-02	Tanabe Seiyaku Co	Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
JP5073948B2 (ja) *	2005-01-31	2012-11-14	田辺三菱製薬株式会社	医薬組成物
MY147375A (en)	2005-01-31	2012-11-30	Mitsubishi Tanabe Pharma Corp	Indole derivatives
CA2595257A1 (en)	2005-02-23	2006-08-31	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
JP5238492B2 (ja)	2005-04-15	2013-07-17	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｇｌｔインヒビターとしてのグルコピラノシル置換（ヘテロアリールオキシ−ベンジル）−ベンゼン誘導体
US7723309B2 (en)	2005-05-03	2010-05-25	Boehringer Ingelheim International Gmbh	Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk)	2005-05-03	2010-08-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en)	2005-05-10	2010-08-10	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
DE102005026762A1 (de)	2005-06-09	2006-12-21	Sanofi-Aventis Deutschland Gmbh	Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
EP1910390B1 (en)	2005-07-27	2010-05-19	Boehringer Ingelheim International GmbH	Glucopyranosyl-substituted ((hetero)cycloalyklethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors
ATE484499T1 (de)	2005-08-30	2010-10-15	Boehringer Ingelheim Int	Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
CA2621314A1 (en)	2005-09-08	2007-03-15	Boehringer Ingelheim International Gmbh	Crystalline forms of 1-chloro-4-(.beta.-d-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
AR056195A1 (es)	2005-09-15	2007-09-26	Boehringer Ingelheim Int	Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
US7745414B2 (en)	2006-02-15	2010-06-29	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
PE20080697A1 (es)	2006-05-03	2008-08-05	Boehringer Ingelheim Int	Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
WO2007140191A2 (en) *	2006-05-23	2007-12-06	Theracos, Inc.	Glucose transport inhibitors and methods of use
DE102006028862A1 (de) *	2006-06-23	2007-12-27	Merck Patent Gmbh	3-Amino-imidazo[1,2-a]pyridinderivate
TWI418556B (zh)	2006-07-27	2013-12-11	Mitsubishi Tanabe Pharma Corp	吲哚衍生物
US20080027014A1 (en) *	2006-07-28	2008-01-31	Tanabe Seiyaku Co., Ltd.	Novel SGLT inhibitors
BRPI0715160A2 (pt)	2006-08-08	2013-06-11	Sanofi Aventis	imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
CA2656847A1 (en)	2006-08-15	2008-02-21	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
TWI499414B (zh)	2006-09-29	2015-09-11	Lexicon Pharmaceuticals Inc	鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ２）的抑制物與其應用方法
CA2667550A1 (en)	2006-10-27	2008-05-02	Boehringer Ingelheim International Gmbh	Crystalline form of 4-(.beta.-d-glucopyranos-1-yl)-1-methyl-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
DE102006053637B4 (de)	2006-11-14	2011-06-30	Sanofi-Aventis Deutschland GmbH, 65929	Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
UY30730A1 (es)	2006-12-04	2008-07-03	Mitsubishi Tanabe Pharma Corp	Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
CN101611032B (zh)	2006-12-04	2012-07-18	詹森药业有限公司	作为抗糖尿病药的含噻吩基的吡喃葡糖基衍生物
US7795228B2 (en) *	2006-12-28	2010-09-14	Theracos, Inc.	Spiroheterocyclic glycosides and methods of use
DE102007008420A1 (de)	2007-02-21	2008-08-28	Merck Patent Gmbh	Benzimidazolderivate
US7846945B2 (en) *	2007-03-08	2010-12-07	Lexicon Pharmaceuticals, Inc.	Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PE20090938A1 (es)	2007-08-16	2009-08-08	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
CA2699285C (en)	2007-09-10	2016-12-13	Ahmed F. Abdel-Magid	Process for the preparation of compounds useful as inhibitors of sodium-dependent glucose transporter (sglt)
DE102007048716A1 (de)	2007-10-11	2009-04-23	Merck Patent Gmbh	Imidazo[1,2-a]pyrimidinderivate
JP5272395B2 (ja)	2007-12-12	2013-08-28	セントラル硝子株式会社	４−デオキシ−４−フルオロ−ｄ−グルコース誘導体の製造方法
UA101004C2 (en)	2007-12-13	2013-02-25	Теракос, Инк.	Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
DE102008017590A1 (de)	2008-04-07	2009-10-08	Merck Patent Gmbh	Glucopyranosidderivate
US8470841B2 (en)	2008-07-09	2013-06-25	Sanofi	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2324002B1 (en) *	2008-08-22	2016-10-05	Theracos Sub, LLC	Processes for the preparation of sglt2 inhibitors
MX2011002166A (es) *	2008-08-28	2011-04-07	Pfizer	Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
US9056850B2 (en)	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
EP2406271A1 (en) *	2008-12-08	2012-01-18	Sanofi	A novel crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010068605A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	Novel polymorphic forms of 4-[(4-methoxyphenyl)methyl]-5-(trifluoromethyl)-1h-pyrazole-3-yl]4-deoxy-4-fluoro-beta-d-glucopyranoside including hydrates thereof and the preparations thereof
WO2010077623A1 (en)	2008-12-08	2010-07-08	Sanofi-Aventis	Intermediates and processes for the preparation of fluoroglycoside derivatives
EP2406270B1 (de) *	2008-12-08	2013-04-17	Sanofi	Verfahren zur herstellung von 4-fluoro-4-desoxy-alpha-d-glucopyranosiden
WO2010068601A1 (en) *	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
EP2395983B1 (en)	2009-02-13	2020-04-08	Boehringer Ingelheim International GmbH	Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
US20110009347A1 (en) *	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
AU2010270202B2 (en)	2009-07-10	2014-04-24	Janssen Pharmaceutica Nv	Crystallisation process for 1-(beta-D-glucopyranosyl)-4-methyl-3- [5-(4-fluorophenyl)-2-thienylmethyl] benzene
ES2443016T3 (es)	2009-08-26	2014-02-17	Sanofi	Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
EP2298782A1 (en)	2009-08-26	2011-03-23	Sanofi-Aventis	Method for producing pyrazole glycoside derivatives
EP2483286B1 (en)	2009-09-30	2016-07-13	Boehringer Ingelheim International GmbH	Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
SI2486029T1 (sl)	2009-09-30	2015-10-30	Boehringer Ingelheim International Gmbh	Postopki za pripravo z glukopiranozilom substituiranih benzil-benzenskih derivatov
CA2774903A1 (en) *	2009-10-02	2011-04-07	Sanofi	Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases
US10610489B2 (en)	2009-10-02	2020-04-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
IN2012DN03299A (no)	2009-10-14	2015-10-23	Janssen Pharmaceutica Nv
US8163704B2 (en)	2009-10-20	2012-04-24	Novartis Ag	Glycoside derivatives and uses thereof
EA021983B1 (ru)	2009-11-02	2015-10-30	Пфайзер Инк.	Производные диоксабицикло[3.2.1]октан-2,3,4-триола
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
SG185525A1 (en)	2010-05-11	2012-12-28	Janssen Pharmaceutica Nv	Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
WO2011153712A1 (en)	2010-06-12	2011-12-15	Theracos, Inc.	Crystalline form of benzylbenzene sglt2 inhibitor
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683704B1 (de)	2011-03-08	2014-12-17	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en)	2011-03-08	2014-10-28	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683701B1 (de)	2011-03-08	2014-12-24	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de)	2011-03-08	2015-04-22	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
AU2012241897C1 (en)	2011-04-13	2017-05-11	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of SGLT2
US9035044B2 (en)	2011-05-09	2015-05-19	Janssen Pharmaceutica Nv	L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
WO2012176804A1 (ja) *	2011-06-20	2012-12-27	キッセイ薬品工業株式会社	グルコピラノシルオキシピラゾール誘導体
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US9192617B2 (en)	2012-03-20	2015-11-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en)	2012-04-10	2015-11-24	Theracos, Inc.	Process for the preparation of benzylbenzene SGLT2 inhibitors
EP2774619B1 (de)	2013-03-04	2016-05-18	BioActive Food GmbH	Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
TR201901110T4 (tr)	2013-04-05	2019-02-21	Boehringer Ingelheim Int	Empagliflozinin terapötik kullanımları.
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en)	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CN113181161A (zh)	2013-04-18	2021-07-30	勃林格殷格翰国际有限公司	药物组合物、治疗方法及其用途
WO2015051484A1 (en)	2013-10-12	2015-04-16	Theracos, Inc.	Preparation of hydroxy-benzylbenzene derivatives
EP2944311A1 (de)	2014-05-16	2015-11-18	BioActive Food GmbH	Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
MA46742A (fr)	2016-11-10	2019-09-18	Boehringer Ingelheim Int	Composition pharmaceutique, méthodes de traitement et leurs utilisations

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2663336B1 (fr) *	1990-06-18	1992-09-04	Adir	Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE69712172T2 (de) *	1996-12-26	2002-10-31	Tanabe Seiyaku Co., Ltd.	Propiophenonderivate und Verfahren zu ihrer Herstellung
JP3055135B2 (ja) *	1996-12-26	2000-06-26	田辺製薬株式会社	プロピオフェノン誘導体及びその製法
EP0953357A1 (en) *	1997-01-17	1999-11-03	Drug Delivery System Institute, Ltd.	Nephrotropic drugs
DE19726167B4 (de) *	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
JP2000080041A (ja) *	1998-03-09	2000-03-21	Tanabe Seiyaku Co Ltd	医薬組成物
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) *	1998-10-02	2000-07-13	Aventis Pharma Gmbh	Arylsubstituierte Propanolaminderivate und deren Verwendung
HU229581B1 (en) *	1999-08-31	2014-02-28	Kissei Pharmaceutical	Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
AU774071B2 (en) *	1999-09-01	2004-06-17	Sanofi-Aventis Deutschland Gmbh	Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
PH12000002657B1 (en) *	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
WO2001068660A1 (en) *	2000-03-17	2001-09-20	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en) *	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) *	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
CA2407538C (en) *	2000-04-28	2007-01-09	Asahi Kasei Kabushiki Kaisha	Novel bicyclic compounds
AU2001268718B2 (en) *	2000-06-29	2006-01-05	Abbott Laboratories	Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
BR0114310A (pt) *	2000-09-29	2003-10-14	Kissei Pharmaceutical	Derivados do glicopiranosiloxibenzilbenzeno e composições medicinais contendo os mesmos
AU2002210990A1 (en) *	2000-11-02	2002-05-15	Ajinomoto Co. Inc.	Novel pyrazole derivatives and diabetes remedies containing the same
CA2429833A1 (en) *	2000-11-30	2002-06-06	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
DE60230591D1 (de) *	2001-02-26	2009-02-12	Kissei Pharmaceutical	Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
EP1364958B1 (en) *	2001-02-27	2010-09-08	Kissei Pharmaceutical Co., Ltd.	Glycopyranosyloxypyrazole derivatives and medicinal use thereof
ATE442148T1 (de) *	2001-04-04	2009-09-15	Ortho Mcneil Janssen Pharm	Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
JP4590159B2 (ja) *	2001-04-04	2010-12-01	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
EP1400529A4 (en) *	2001-05-30	2007-12-19	Kissei Pharmaceutical	GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
US7399777B2 (en) *	2001-08-31	2008-07-15	Sanofi-Aventis Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
US6884812B2 (en) *	2001-08-31	2005-04-26	Aventis Pharma Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
PL208515B1 (pl) *	2001-08-31	2011-05-31	Sanofi Aventis Deutschland	Pochodne diarylocykloalkilowe, środki lecznicze zawierające te związki oraz ich zastosowanie jako aktywatorów PPAR
WO2003020737A1 (en) *	2001-09-05	2003-03-13	Bristol-Myers Squibb Company	O-pyrazole glucoside sglt2 inhibitors and method of use
DE10231370B4 (de) *	2002-07-11	2006-04-06	Sanofi-Aventis Deutschland Gmbh	Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) *	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel

2002
- 2002-12-12 DE DE10258008A patent/DE10258008B4/de not_active Expired - Fee Related
2003
- 2003-11-28 RS YUP-2005/0432A patent/RS50908B/sr unknown
- 2003-11-28 PT PT03782250T patent/PT1572708E/pt unknown
- 2003-11-28 SI SI200330284T patent/SI1572708T1/sl unknown
- 2003-11-28 JP JP2004557953A patent/JP4806193B2/ja not_active Expired - Fee Related
- 2003-11-28 EP EP03782250A patent/EP1572708B1/de not_active Expired - Lifetime
- 2003-11-28 AU AU2003289911A patent/AU2003289911B2/en not_active Ceased
- 2003-11-28 NZ NZ540695A patent/NZ540695A/en not_active IP Right Cessation
- 2003-11-28 PL PL375790A patent/PL212080B1/pl unknown
- 2003-11-28 CA CA2508226A patent/CA2508226C/en not_active Expired - Fee Related
- 2003-11-28 DK DK03782250T patent/DK1572708T3/da active
- 2003-11-28 OA OA1200500177A patent/OA12972A/en unknown
- 2003-11-28 MX MXPA05005821A patent/MXPA05005821A/es active IP Right Grant
- 2003-11-28 HR HR20050532A patent/HRP20050532A2/xx not_active Application Discontinuation
- 2003-11-28 BR BR0317283-0A patent/BR0317283A/pt not_active IP Right Cessation
- 2003-11-28 ME MEP-409/08A patent/MEP40908A/xx unknown
- 2003-11-28 CN CNB2003801057098A patent/CN1304406C/zh not_active Expired - Fee Related
- 2003-11-28 WO PCT/EP2003/013455 patent/WO2004052903A1/de not_active Ceased
- 2003-11-28 RU RU2005121893/04A patent/RU2339641C2/ru not_active IP Right Cessation
- 2003-11-28 UA UAA200506789A patent/UA81136C2/uk unknown
- 2003-11-28 ES ES03782250T patent/ES2261993T3/es not_active Expired - Lifetime
- 2003-11-28 AT AT03782250T patent/ATE323713T1/de active
- 2003-11-28 DE DE50303067T patent/DE50303067D1/de not_active Expired - Lifetime
- 2003-11-28 KR KR1020057010457A patent/KR101160061B1/ko not_active Expired - Fee Related
- 2003-12-03 GT GT200300268A patent/GT200300268A/es unknown
- 2003-12-09 JO JO2003167A patent/JO2353B1/en active
- 2003-12-10 HN HN2003000408A patent/HN2003000408A/es unknown
- 2003-12-10 TW TW092134766A patent/TWI320044B/zh not_active IP Right Cessation
- 2003-12-10 PE PE2003001249A patent/PE20040771A1/es not_active Application Discontinuation
- 2003-12-11 MY MYPI20034745A patent/MY139302A/en unknown
- 2003-12-11 AR ARP030104574A patent/AR042437A1/es unknown
- 2003-12-12 UY UY28122A patent/UY28122A1/es unknown
- 2003-12-12 PA PA20038592301A patent/PA8592301A1/es unknown
- 2003-12-12 US US10/734,573 patent/US20040259819A1/en not_active Abandoned
- 2003-12-12 SV SV2003001690A patent/SV2004001690A/es active IP Right Grant
2005
- 2005-04-26 ZA ZA200503365A patent/ZA200503365B/en unknown
- 2005-05-02 CR CR7820A patent/CR7820A/es unknown
- 2005-05-30 IL IL168876A patent/IL168876A/en not_active IP Right Cessation
- 2005-06-10 EC EC2005005853A patent/ECSP055853A/es unknown
- 2005-06-10 TN TNP2005000160A patent/TNSN05160A1/en unknown
- 2005-06-10 MA MA28327A patent/MA27560A1/fr unknown
- 2005-06-30 NO NO20053201A patent/NO330299B1/no not_active IP Right Cessation
2006
- 2006-06-21 CY CY20061100833T patent/CY1105621T1/el unknown
2010
- 2010-05-25 US US12/786,943 patent/US20100261664A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PA8592301A1 (es)	2004-07-26
TNSN05160A1 (en)	2007-05-14
AU2003289911B2 (en)	2009-09-17
CR7820A (es)	2008-11-25
AU2003289911A1 (en)	2004-06-30
EP1572708B1 (de)	2006-04-19
MEP40908A (en)	2011-02-10
UY28122A1 (es)	2004-07-30
UA81136C2 (en)	2007-12-10
DE50303067D1 (de)	2006-05-24
AR042437A1 (es)	2005-06-22
MA27560A1 (fr)	2005-10-03
PL212080B1 (pl)	2012-08-31
IL168876A (en)	2010-06-30
RS20050432A (sr)	2007-06-04
HRP20050532A2 (en)	2006-09-30
JP4806193B2 (ja)	2011-11-02
CA2508226A1 (en)	2004-06-24
DE10258008A1 (de)	2004-07-08
TWI320044B (en)	2010-02-01
KR20050085482A (ko)	2005-08-29
NO330299B1 (no)	2011-03-28
DE10258008B4 (de)	2006-02-02
EP1572708A1 (de)	2005-09-14
PT1572708E (pt)	2006-07-31
MXPA05005821A (es)	2005-08-29
SI1572708T1 (sl)	2006-08-31
SV2004001690A (es)	2004-03-19
JP2006510644A (ja)	2006-03-30
PE20040771A1 (es)	2005-01-21
US20040259819A1 (en)	2004-12-23
RU2339641C2 (ru)	2008-11-27
KR101160061B1 (ko)	2012-06-26
PL375790A1 (en)	2005-12-12
GT200300268A (es)	2004-03-03
WO2004052903A1 (de)	2004-06-24
RS50908B (sr)	2010-08-31
MY139302A (en)	2009-09-30
NZ540695A (en)	2007-02-23
ATE323713T1 (de)	2006-05-15
OA12972A (en)	2006-10-13
JO2353B1 (en)	2006-12-12
ECSP055853A (es)	2005-09-20
CN1304406C (zh)	2007-03-14
HK1084123A1 (en)	2006-07-21
RU2005121893A (ru)	2006-01-20
TW200418870A (en)	2004-10-01
CN1723214A (zh)	2006-01-18
BR0317283A (pt)	2005-11-08
DK1572708T3 (da)	2006-08-21
NO20053201D0 (no)	2005-06-30
ZA200503365B (en)	2006-11-29
CA2508226C (en)	2011-12-20
US20100261664A1 (en)	2010-10-14
HN2003000408A (es)	2006-01-07
CY1105621T1 (el)	2010-12-22
ES2261993T3 (es)	2006-11-16

Publication	Publication Date	Title
NO20053201L (no)	2005-08-04	Nye heterocykliske fluorglukosidderivater, legemidler inneholdende disse forbindelser og deres anvendelse.
NO20070176L (no)	2007-03-09	Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav
NO20050649L (no)	2005-04-01	Nye tiofenylglykosidderivater, fremgangsmate for fremstilling derav, medikamenter omfattende disse forbindelser og anvendelse derav
NO20093060L (no)	2005-06-07	Spirosykliske sykloheksanderivater
NO20066055L (no)	2007-01-24	Pyridinderivater
NO20063925L (no)	2006-09-01	Indazolderivater som inhibitorer av hormonsensitiv lipase
NO20060001L (no)	2006-03-02	Nye P2X7-reseptorantagonister og deres anvendelse
NO20071593L (no)	2007-05-22	Pyrimidinderivater
NO20042372L (no)	2004-06-07	Nye 1,2,4-tiadiazolderivater som melanokortinreseptormodulatorer
NO20070731L (no)	2007-02-19	Heterocykliske forbindelser.
NO20056132L (no)	2006-01-26	Krystallinsk form av beta2 adrenergisk receptoragonist
NO20052028L (no)	2005-06-03	Pyridinderivater som CB2 reseptor modulatorer
DK2279737T3 (da)	2013-02-11	Heterocycliske forbindelser, der er aktive som beta-lactamaseinhibitorer
NO20055135L (no)	2005-12-14	Fenylguinoliner og deres anvendelse som ostrogenreseptormodulatorer
NO20066050L (no)	2007-02-05	Substituerte indazoler, sammensetninger inneholdende disse samt fremstilling og anvendelse derav
NO20053215D0 (no)	2005-06-30	Pyrazolderivater med anvendelse som COX-1-inhibitorer.
NO20053775D0 (no)	2005-08-08	Diazepinoindol derivater som kinaseinhibitorer.
NO20071108L (no)	2007-02-27	Nye 4-benzylidenpiperidinderivater
NO20071504L (no)	2007-05-25	Pyrimidinderivanter.
DK1506185T3 (da)	2006-10-02	Forbindelser og deres anvendelse som 5-HT-inhibitorer
NO20072005L (no)	2007-06-15	Nye heterocykliske amider
NO20076680L (no)	2008-04-30	Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter
NO20083325L (no)	2008-09-18	Karbonater av antibiotiske fenicolforbindelser
NO20071159L (no)	2007-03-26	Prodmedikamentsubstituerte benzoksazoler som ostrogene midler
ATE355265T1 (de)	2006-03-15	Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren

Legal Events

Date	Code	Title	Description
2015-06-22	MM1K	Lapsed by not paying the annual fees